Skip to content

Santero Therapeutics

Active Private limited companyfounded 2021active for 5 yearsRue Clément Ader 10, 6041 CharleroiKBO/BCE: BE 0765.790.155

Lifetime

5 annual accounts with figures on one time axis
peak of €991,461 in 2025
€991,461▲ 111%
lowest -€2.3m in 2024
-€2.1m▲ €154,563
peak of €3.6m in 2025
€3.6m▲ 43.7%
€519,996▲ 10.2%
peak of 11.9 FTE in 2025
11.9 FTE▲ 41.7%
Board15 names since 2021all names
5 directors and 4 others
Owners2 names in the annual accounts
27.67% and 1 other
Documentsfilings and deeds
24-07-20267 days before the deadline
2025abbreviated format
Gross margin from €469,675 to €991,461Loss of €2.1mStaff from 8.4 FTE to 11.9 FTE1 director appointed, 1 resignation 05-05Capital increase of €2,954,340 13-03Registered office moved within Charleroi 12-02

Key points

from the 2025 annual accounts

Equity

€3.6m ▲ 43.7%
€2.5m2024€3.6m2025

Equity rose in 2025 from €2.5m to €3.6m.

Losses

-€5.9m in five years
-0.22021-0.42022-0.92023-2.32024-2.12025

Every financial year from 2021 to 2025 closed with a loss. 2024 was the heaviest.

Turnover

≈ €2.4m estimated

The accounts state no turnover.

Staff

12 employees on 31-12-2025
1020212120223120231032024652025

In 2025, 6 employees joined and 5 left.

Board

1 joined · 1 left

1 director joined and 1 left, the latest change on 18-12-2025. 5 are in office now.

Position in the sector

-€2.1m

Lower net result than 89% of companies in research and development. The sector median is €423, over 343 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 224 companies had the same profile as Santero Therapeutics has now. Each dot is one company, two years later.

88.4%
were still trading
7.1%
stopped another way
4.0%
went bankrupt
  • Small
  • 5 to 10 years old
  • solvency 30% or more
  • a loss of 10% of the balance sheet or more

Another 0.4% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,965 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 224 companies, not a prediction for Santero Therapeutics. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Daily manager,
Director, since 26-05-2023
Director, , since 26-05-2023
Director, since 08-05-2024
Director, since 08-05-2024
Auditor,
and 1 other
  • 27.67%score equity €24.6m (2025) · annual accounts 2025 of
  • 15.81%equity €11.45bn (2025) · annual accounts 2025 of
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0765790155
New daily management delegate appointed, resigned · acts as permanent representative · Gazette deed
and act as permanent representatives Board meeting of 01-12-2025 · Gazette deed
1 director appointed, 1 resignation resigns · appointed · acts as permanent representative · General meeting of 23-12-2024 · Gazette deed
All 25 events

Comparable companies

same main activity, similar in size and age
Company
Santero Therapeutics Charleroi €4.2m €1.0m 87.5% 11.9
CM4Cure Liège €4.6m €0.6m 38.8% 9.4
K5 Therapeutics Leuven €3.6m €2.6m 83.1% 17.8
Cryptobiotix Ghent €5.7m €3.9m 64.9% 15.8
CureVac Belgium Ottignies-Louvain-la-Neuve €3.6m €5.0m 9.4% 10.2
AmphiStar Ghent €10.1m €2.1m 63.2% 13.5
anicells Niel €1.8m €1.2m 10.1% 13.8

These companies have the same main activity as Santero Therapeutics: research and development on biotechnology (NACE 72101). They are comparable in size and age: total assets between €1.8m and €10m, founded between 2019 and 2022.

Official details

Source: KBO
Status
Active since 29-03-2021Normal situation
Registered office
36 active companies are registered at this addressOf these, 3 started in the 12 months before 19 November 2026. Source: KBO register, as of 19 November 2026.
Activity
Research and development on biotechnologyNACE 72101and 1 other
Joint committee
207White-collar workers in the chemical industry · annual accounts 2025
Establishment units
2.317.400.4726041 Charleroi, since 29-03-2021
2.325.552.1351050 Ixelles, since 01-12-2021and 1 other
Financial year end
31 December
Peppol
Reachable since 21-10-2026
Company details

Annual accounts 2025

€4.2m▲ 38.5%
Employeeson 31-12-2025
12▲ 9.1%
Filing
Filed on 24-07-2026, 7 days before the end of the filing period
Financials

Insights on Santero Therapeutics

Santero Therapeutics files the abbreviated format. That format states no turnover. The gross margin rose from -€104,804 in 2021 to €991,461 in 2025.

In June 2023, five directors stepped down. In February 2026, the Official Gazette published the appointment of as managing director.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about Santero Therapeutics

What is the company number of Santero Therapeutics?
The company number of Santero Therapeutics is 0765.790.155. The VAT number is the same number with BE in front: BE 0765.790.155.
Where is Santero Therapeutics based?
The registered office is at Rue Clément Ader 10, 6041 Charleroi.Company details
What does Santero Therapeutics do?
According to the KBO register, the main activity is research and development on biotechnology (NACE 72101).
What is the legal form of Santero Therapeutics?
Santero Therapeutics is a private limited company (BV).
When was Santero Therapeutics founded?
Santero Therapeutics was founded on 29-03-2021.
Is Santero Therapeutics still active?
Yes, Santero Therapeutics is an active enterprise in the KBO register.
How many employees does Santero Therapeutics have?
Santero Therapeutics had an average of 11.9 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
Which joint committee does Santero Therapeutics fall under?
In its 2025 annual accounts, Santero Therapeutics states joint committee 207 (White-collar workers in the chemical industry).
What is the turnover of Santero Therapeutics?
The turnover in financial year 2025 is about €2.4m. This figure is estimated from the gross margin of €991,461 and 2,136 comparable companies of the same size. It probably lies between €1.4m and €4.1m. It is a rough estimate.
Is Santero Therapeutics profitable?
In financial year 2025, Santero Therapeutics made a loss of €2.1m.
Where can I find the annual accounts of Santero Therapeutics?
Santero Therapeutics filed 5 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of Santero Therapeutics due?
Santero Therapeutics must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.